

Please type a plus sign (+) inside this box →



RECEIVED

JUL 3 2002

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TECH CENTER 1600/2900

Complete if Known



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MJM		2,677,700		Jackson et al.	05-04-1954	
MJM		3,036,118		Jackson et al.	05-22-1962	
MJM		3,535,307		Moss et al.	10-20-1970	
MJM		3,829,506		Schmolka et al.	08-13-1974	
MJM		4,517,686		Ruoslahti et al.	05-21-1985	
MJM		4,578,079		Ruoslahti et al.	03-25-1986	
MJM		4,589,881		Pierschbacher et al.	05-20-1986	
MJM		4,938,763		Dunn et al.	07-03-1990	
MJM		5,041,380		Ruoslahti et al.	08-20-1991	
MJM		5,149,780		Plow et al.	09-22-1992	
MJM		5,169,930		Ruoslahti et al.	12-08-1992	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)				

Examine Signature	M. Marich	Date Considered	9/16/04
----------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

RECEIVED

Please type a plus sign (+) inside this box →



JUL 3 2002

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TECH CENTER 1000/2500

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Slepian
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

Sheet 2 of 4

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
mm		KUMAILLEY, et al., "Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1," <i>FEBS</i> , 291(1): 50-54 (1991).	
mm		BECK, et al., "Structure and function of laminin: anatomy of a multidomain glycoprotein," <i>FASEB J.</i> , 4(2):148-160 (1990).	
mm		GRAF, et al., "A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor," <i>Biochem.</i> , 26(22):6896-6900 (1987).	
mm		GRAF, et al., "Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding," <i>Cell</i> , 48(6):989-996 (1987).	
mm		GRANT, et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro," <i>Cell</i> , 58(5):933-943 (1989).	
mm		GURRATH, et al., "Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides," <i>Eur. J. Biochem.</i> , 210(3) 911-921 (1992).	
mm		IWAMOTO, et al., "YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation," <i>Science</i> , 238(4830):1132-1134 (1987).	
mm		KAUFMANN, "Heat shock proteins and the immune response," <i>Immunol. Today</i> , 11(4):129-137 (1990).	
mm		KLEINMAN, et al., "Basement membrane complexes with biological activity," <i>Biochem.</i> , 25(2):312-318 (1986).	
mm		KLEINMAN, et al., "Biological activities of laminin," <i>J. Cell Biochem.</i> , 27(4):317-325 (1985).	

Examiner's Signature	<i>M. Slepian</i>	Date Considered	9/14/02
----------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box →



JUL 3 2002

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TECH CENTER 1600/2000

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)



Complete if Known

Application Number	10/072,766
Filing Date	February 8, 2002
First Named Inventor	Marvin Sleplan
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	MJS 104

Sheet	3	of	4
-------	---	----	---

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
mm	✓	LINDQUIST, "The heat-shock response," <i>Ann. Rev. Biochem.</i> , 55:1151-1191 (1986).	
mm	✓	LINDQUIST, et al., "The heat-shock proteins," <i>Annu. Rev. Genet.</i> , 22:631-677 (1988).	
mm	✓	MOHRI, et al., "Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets," <i>Amer. J. Hem.</i> , 37(1):14-19 (1991).	
mm	✓	MORIMOTO, "Heat shock: the role of transient inducible responses in cell damage, transformation, and differentiation," <i>Cancer Cells</i> , 3(8):295-301 (1991).	
mm	✓	MOVER, "HSFs and HSPs - a stressful program on transcription factors and chaperones." <i>Stress Proteins, and the Heat Shock Response</i> , sponsored by Cold Spring Harbor Laboratory (Cold Spring Harbor, NY USA April 29-May 2, 1991) <i>New Biol.</i> 3:855-859 (1991).	
mm	✓	MOVER, et al., "Heat shock protein, in <i>Heat Shock Response</i> (CRC Press, 1991) pp. 41-127.	
mm	✓	PELHAM, "Heat shock and the sorting of luminal ER proteins," <i>EMBO J.</i> , 8(11):3171-3176 (1989).	
mm	✓	PELHAM, "Speculations on the functions of the major heat shock and glucose-regulated proteins," <i>Cell</i> , 46(7): 959-961 (1986).	
mm	✓	PIERSCHBACHER, et al., "Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion," <i>J. Biol. Chem.</i> , 262(36): 17294-17298 (1987).	
mm	✓	SAKAMOTO, et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH ₂ ," <i>Cancer Res.</i> , 51(3):903-906 (1991).	

Examiner's Signature	M. Marich	Date Considered	9/16/04
----------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

RECEIVED

Please type a plus sign (+) inside this box →



JUL 3 2002


PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(Use as many sheets as necessary)

Complete if Known

Application Number

10/072,766

Filing Date

February 8, 2002

First Named Inventor

Marvin Sleplan

Group Art Unit

1636

Examiner Name

Attorney Docket Number

MJS 104

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
mm	✓	SCARBOROUGH, et al., "Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa," <i>J. Biol. Chem.</i> 268(2): 1066-1073 (1993).	
mm	✓	SCHLESINGER, "Heat shock proteins," <i>J. Biol. Chem.</i> , 265(21):12111-12114 (1990).	
mm	✓	SCHLESINGER, <u>Heat Shock: from bacterial to man</u> (Cold Spring Harbor, Cold Spring Harbor, NY 1982).	
mm	✓	TAY, et al., "Activity toward thrombin-antithrombin of heparin immobilized on two hydrogels," <i>Biomaterials</i> , 10(1): 11-15 (1989).	

Examiner's Signature

M. Thannich

Date Considered

9/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+